ijms-logo

Journal Browser

Journal Browser

Advances in Biomedical and Tissue Engineering Strategies to Cross the Blood–Brain Barrier for Next-Generation Treatments against Neurodegenerative Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1239

Special Issue Editors


E-Mail Website
Guest Editor
3D Bioprinting and Bioimaging Lab, Institute of Biochemistry and Cell Biology (IBBC) - National Research Council (CNR), International Campus “A. Buzzati-Traverso”, Monterotondo Scalo, Rome, Italy
Interests: 3D bioprinting; organ and tissue models; organs-on-a-chip; tissue engineering; hepatology; gastroenterology; neuroscience

E-Mail Website
Guest Editor
Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy
Interests: neurodegenerative diseases; neuroinflammation; Alzheimer’s disease; therapeutic strategies

Special Issue Information

Dear Colleagues,

The global burden of neurological disorders, including, among others, Parkinson’s disease (PD), Alzheimer’s disease (AD), and other types of dementia, is rapidly growing at a worldwide level, representing an urgent global health challenge. With the aging population, the neurodegenerative disease-associated disability and mortality rates are expected to skyrocket dramatically over the next few decades if novel and effective cures are not available soon. Furthermore, with the aim of efficaciously treating any central nervous system (CNS) disease, from Alzheimer’s to Parkinson’s, one must address the issue of overcoming the blood–brain barrier (BBB), which represents the main obstacle for effective and safe drug delivery to the whole brain or to a specific area of interest. The BBB is indeed a protective yet semipermeable interface of the neurovascular unit that mediates communication between the CNS and peripheral one. As a matter of fact, because of this selective biological barrier, to reach a significant drug concentration at the site of action in the CNS, the administration of high and repeated doses of the therapeutic agent is needed, thereby causing possible harmful and undesired effects. Taking all of this into account, there is still an urgent need for more advanced, safe, and tailored treatment strategies. Thus, the development of a new generation of neuroprotective cures leveraging emerging nanotechnologies, smart pharmacological tools, and cutting-edge tissue engineering approaches for drug delivery across the BBB will represent a tremendous step forward in this appealing biomedical research field, and in turn, it may point the way to accelerating the development and approval of novel drugs. 

This Special Issue aims to collect original research articles and reviews on the state-of-the-art of novel therapeutic approaches for the prevention and treatment of neurodegenerative diseases, with special attention to the most promising biomedical strategies to overcome the blood–brain barrier issue. Advances, progresses, and open challenges in the search for efficacious and safe cures against neurological disorders based on innovative tissue engineering strategies and nanotechnological solutions to circumvent the biological obstacle of the BBB will be the focus of interest in this Special Issue.

Dr. Manuele Gori
Dr. Livia La Barbera
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegenerative diseases
  • Alzheimer’s disease
  • CNS
  • blood–brain barrier
  • drug delivery systems
  • nanocarriers
  • nanomedicine
  • tissue engineering
  • theranostics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2756 KiB  
Article
In Vivo Evaluation of Nose-to-Brain Delivery of Liposomal Donepezil, Memantine, and BACE-1 siRNA for Alzheimer’s Disease Therapy
by David Lee, Andrew M. Shen, Milin Shah, Olga B. Garbuzenko and Tamara Minko
Int. J. Mol. Sci. 2024, 25(19), 10357; https://doi.org/10.3390/ijms251910357 - 26 Sep 2024
Viewed by 334
Abstract
Our study took an innovative approach by evaluating, in vivo, the efficacy of intranasal (IN) administration of liposomal formulations of donepezil, memantine, and beta-site amyloid precursor protein-cleaving enzyme (BACE-1) siRNA, and their combination as a “triple-drug therapy” in treating Alzheimer’s disease (AD). Female [...] Read more.
Our study took an innovative approach by evaluating, in vivo, the efficacy of intranasal (IN) administration of liposomal formulations of donepezil, memantine, and beta-site amyloid precursor protein-cleaving enzyme (BACE-1) siRNA, and their combination as a “triple-drug therapy” in treating Alzheimer’s disease (AD). Female APP/PS1 homozygous, transgenic mice were used as an AD model. The spatial short-term memory of the APP/PS1 mice was evaluated by a Y-maze behavioral test. IN-administered formulations demonstrated better short-term memory recovery than oral administration. Triple-drug therapy induced short-term memory recovery and lowered beta-amyloid (Aβ) 40 and 42 peptide levels and BACE-1 mRNA expression. Additionally, inflammatory cytokine mRNA expression was downregulated. This innovative approach opens new possibilities for Alzheimer’s disease treatment and nose-to-brain delivery. Full article
Show Figures

Figure 1

15 pages, 8170 KiB  
Article
Assessment of Mannitol-Induced Chronic Blood–Brain Barrier Dysfunction In Vivo Using Magnetic Resonance
by Ana Sampedro-Viana, Sabela Fernández-Rodicio, José Castillo, Pablo Hervella, María Luz Alonso-Alonso and Ramón Iglesias-Rey
Int. J. Mol. Sci. 2024, 25(18), 9792; https://doi.org/10.3390/ijms25189792 - 10 Sep 2024
Viewed by 580
Abstract
The blood–brain barrier (BBB) is essential for protection and plays a crucial role in chronic neurological disorders like small-vessel disease and Alzheimer’s disease. Its complexity poses significant challenges for effective diagnostics and treatments, highlighting the need for novel animal models and comprehensive BBB [...] Read more.
The blood–brain barrier (BBB) is essential for protection and plays a crucial role in chronic neurological disorders like small-vessel disease and Alzheimer’s disease. Its complexity poses significant challenges for effective diagnostics and treatments, highlighting the need for novel animal models and comprehensive BBB dysfunction studies. This study investigates chronic BBB dysfunction induction using osmotic disruption via mannitol in healthy adult male Sprague Dawley rats over 12 weeks. Group 1 received 1 bolus/week (2.0 g/kg), Group 2 received 3 boluses/week (1.5 g/kg), and Group 3 received 3 boluses/week (2.5 g/kg). BBB dysfunction was assessed using gadolinium (Gd) infusion and MRI to evaluate location, severity, evolution, and persistence. MR spectroscopy (MRS) examined the brain metabolism changes due to intravenous mannitol, with T2-weighted MRI assessing brain lesions. Biomarkers of neuroinflammation were analyzed in the highest mannitol dose group. Our data show chronic BBB dysfunction primarily in the cortex, hippocampus, and striatum, but not in the corpus callosum of rats under periodic mannitol dosing in groups 1 and 2. MRS identified a distinctive metabolite signature, including changes in alanine, choline, and N-acetyl aspartate in the striatum of Group 1. No significant differences were found in the serum levels of all pro- and anti-inflammatory cytokines analyzed in the high-dose Group 3. This study underscores the feasibility and implications of using osmotic disruption to model chronic BBB dysfunction, offering insights for future neuroprotection and therapeutic strategies research. Full article
Show Figures

Figure 1

Back to TopTop